Cytokinetics presented new data related to aficamten at the European Society of Cardiology Congress 2025 in Madrid, Spain.
Additional data from MAPLE-HCM showed that aficamten improves cardiac structure and function compared to metoprolol.
Analysis revealed an annual incidence rate of atrial fibrillation with aficamten at 1.5%, consistent with expected rates in prediction models.
Superiority in Cardiac Structure
Aficamten superior to metoprolol in improving diastolic function, reducing LVOT obstruction contributors, and decreasing maximal wall thickness.
Safety Profile
Longer-term data confirm the safety profile of aficamten, with real-world dosing strategies strengthening the evidence base.
FDA Review
Aficamten is under FDA review with a target action date of December 26, 2025, for a New Drug Application.
- The additional data from MAPLE-HCM emphasized the superiority of aficamten over metoprolol in improving cardiac structure and function.
- New analysis on atrial fibrillation rates with aficamten align with expected rates in patient prediction models, highlighting its safety and efficacy.
The presented data at the ESC Congress 2025 further support the potential of aficamten in improving cardiac outcomes for patients with hypertrophic cardiomyopathy.